Investors Buy Large Volume of Call Options on Insmed (NASDAQ:INSM)

Insmed, Inc. (NASDAQ:INSM) saw unusually large options trading on Thursday. Stock investors bought 17,155 call options on the company. This represents an increase of 469% compared to the typical volume of 3,017 call options.

Insmed Stock Performance

NASDAQ INSM traded up $32.55 on Thursday, reaching $131.57. The stock had a trading volume of 5,726,753 shares, compared to its average volume of 3,066,464. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.47 and a quick ratio of 4.10. The company has a market cap of $28.52 billion, a P/E ratio of -22.71 and a beta of 0.81. The firm has a fifty day moving average of $104.17 and a two-hundred day moving average of $129.42. Insmed has a 1-year low of $90.39 and a 1-year high of $212.75.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.63. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The firm had revenue of $425.49 million during the quarter, compared to analysts’ expectations of $393.74 million. During the same period in the previous year, the firm earned ($1.70) EPS. The company’s quarterly revenue was up 296.1% compared to the same quarter last year. On average, equities research analysts anticipate that Insmed will post -2.43 EPS for the current year.

Insider Activity at Insmed

In other Insmed news, CEO William Lewis sold 21,398 shares of the stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $103.32, for a total value of $2,210,841.36. Following the completion of the sale, the chief executive officer directly owned 258,917 shares of the company’s stock, valued at $26,751,304.44. This represents a 7.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Sara Bonstein sold 2,404 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $245,857.08. Following the completion of the sale, the chief financial officer owned 69,082 shares of the company’s stock, valued at $7,065,016.14. This represents a 3.36% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 54,590 shares of company stock worth $5,793,738. 2.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Insmed

Several institutional investors have recently added to or reduced their stakes in the business. E. Ohman J or Asset Management AB grew its stake in Insmed by 48.7% in the 2nd quarter. E. Ohman J or Asset Management AB now owns 7,789 shares of the biopharmaceutical company’s stock valued at $830,000 after buying an additional 2,550 shares in the last quarter. Handelsbanken Fonder AB increased its position in shares of Insmed by 180.9% during the second quarter. Handelsbanken Fonder AB now owns 189,581 shares of the biopharmaceutical company’s stock valued at $20,213,000 after buying an additional 122,100 shares during the period. Wealthcare Advisory Partners LLC bought a new position in shares of Insmed in the second quarter valued at approximately $498,000. FNY Investment Advisers LLC purchased a new position in shares of Insmed during the 2nd quarter valued at $138,000. Finally, PensionDanmark Pensionsforsikringsaktieselskab grew its position in Insmed by 8.0% during the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 31,393 shares of the biopharmaceutical company’s stock worth $3,347,000 after buying an additional 2,338 shares in the last quarter.

Analyst Ratings Changes

INSM has been the topic of several research analyst reports. Guggenheim reaffirmed a “buy” rating and set a $207.00 price objective on shares of Insmed in a research note on Friday, July 10th. Wells Fargo & Company increased their price target on Insmed from $160.00 to $161.00 and gave the stock an “overweight” rating in a report on Wednesday, July 15th. JPMorgan Chase & Co. cut their price objective on Insmed from $180.00 to $179.00 and set an “overweight” rating on the stock in a report on Monday, June 8th. Mizuho set a $192.00 target price on Insmed in a research note on Tuesday, June 16th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $235.00 price target on shares of Insmed in a research note on Tuesday, July 28th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $209.35.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.